UCB has acquired Engage Therapeutics for up to $270M.
“Like UCB, Engage is a company with a deep-seated passion in epilepsy. Several of Engage’s founders and leaders have personal connections to epilepsy and have been active in the epilepsy community for quite some time.”
Charl van Zyl, Executive Vice President UCB
The acquisition is for up to $270M because UCB is offering $125M in cash and up to $145M based on the completion of certain milestones related to the launch of a Staccato Alprazolam, an epilepsy medicine.